Evidence map›Paper›PMID 42644317›Full record

ArticleBritish journal of haematology2026

The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.

Rory M Shallis, Jennifer VanOudenhove, Namrata Chandhok, Justin Watts, Deepa Jeyakumar, Daniel R Reed, Jan Phillip Bewersdorf, Diane Durecki, Scott Boerner, Richard F Little and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Rory M ShallisSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0002-8542-2944
Jennifer VanOudenhoveSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0001-8206-5542
Namrata ChandhokDivision of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
Justin WattsDivision of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.ORCID https://orcid.org/0000-0001-5213-5482
Deepa JeyakumarDivision of Hematology & Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA.
Daniel R ReedSection of Hematology and Oncology, Department of Internal Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA.
Jan Phillip BewersdorfSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0003-3352-0902
Diane DureckiSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut, USA.
Scott BoernerSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0003-1388-9665
Richard F LittleCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA.
Steven D GoreCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA.
Jing LiDepartment of Oncology, Wayne State University School of Medicine, Detroit, Michigan, USA.ORCID https://orcid.org/0000-0002-9924-1386
Xun BaoDepartment of Oncology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Li ChenMolecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0001-7973-5912
Sayak GhatakMolecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0002-3431-9955
Thomas PrebetSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut, USA.
Ranjit S BindraDepartment of Therapeutic Radiology, Yale University, New Haven, Connecticut, USA.
Amer M ZeidanSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0001-7017-8160
Stephanie HaleneSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0002-2737-9810

Funding

ViKTriY-PC Consortium Phase II SupplementUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · 2014 to 2026
$22.2M
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AMLR01CA266604 · NCI · YALE UNIVERSITY · PI Ranjit Bindra, Stephanie Halene · 2022 to 2026
$3.3M
Blood Cancer UnitedFrederick A. DeLuca FoundationNCI NIH HHS R01 CA266604NCI NIH HHS UM1 CA186689NCI NIH HHS UM1CA186689NIH HHS 1R01CA266604
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acute myeloid leukaemiaAMLIDHMDSmyelodysplasticPARP

Identifiers

PMID42644317
PMCPMC13674138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.